Previous 10 | Next 10 |
Miragen Therapeutics (NASDAQ: MGEN ) : Q2 GAAP EPS of -$0.12 beats by $0.05 . More news on: Miragen Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding triggered Exploratory preclinical safety and pharmacokinetic data for MRG-229 expected before year end Plan to receive guidance from the FDA o...
BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer ...
FRANKFURT, Germany and BOULDER, Colo., July 28, 2020 (GLOBE NEWSWIRE) -- Goethe University, University Hospital Frankfurt and miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today annou...
Natuzzi (NYSE: NTZ ) +131% on renewing its securitization facility. More news on: Natuzzi S.p.A., Miragen Therapeutics, Theratechnologies Inc., Stocks on the move, Read more ...
Buy Penny Stocks To Make Money Or A Mocha Frap With A Sugar Crash? Can you make money with penny stocks ? Smart investors who understand how to make money with penny stocks have plenty of opportunities especially right now. However, most penny stock investors will ultimately lose money but ...
miRagen Therapeutics (NASDAQ: MGEN ) jumps ~39% AH, on the heels of U.S. Orphan Drug tag for Cobomarsen for T-cell lymphoma. More news on: Miragen Therapeutics, Healthcare stocks news, Stocks on the move, Read more ...
BOULDER, Colo., July 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug d...
Liquid Media (NASDAQ: YVR ) +63% . More news on: Liquid Media Group Ltd., Milestone Pharmaceuticals Inc., CymaBay Therapeutics, Inc., Stocks on the move, , Read more ...
BOULDER, Colo., July 22, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its second quarter 2020 financial results after the fina...
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...